Hepatitis C: Boehringer Ingelheim Corporation's Faldaprevir Granted Accelerated Assessment From European Medicines Agency
Published: Nov 26, 2013
INGELHEIM, Germany--(BUSINESS WIRE)--For media outside of the U.S.A., UK and Canada only. The application for European marketing authorisation of faldaprevir*, a potent second generation oral protease inhibitor, has been fully validated and granted accelerated assessment by the European Medicines Agency (EMA).5,6 Boehringer Ingelheim is seeking marketing approval of faldaprevir* in combination with pegylated interferon and ribavirin (PegIFN/RBV) for the treatment of a broad range of patients with genotype-1 (GT-1) hepatitis C, including difficult-to-cure populations such as those with HIV co-infection or advanced liver disease.
Help employers find you! Check out all the jobs and post your resume.